Prognostic Factors in Univariate Analyses
| Factor . | N . | 5-Year Survival (%) . | P . | |
|---|---|---|---|---|
| . | . | . | Wilcoxon Test . | Log-Rank Test . |
| International Prognostic Index | ||||
| 0-2 | 57 | 74 | <.0001 | <.0001 |
| 3-4 | 21 | 23 | ||
| WHO performance status | ||||
| 0-1 | 67 | 69 | <.0001 | <.0001 |
| 2-4 | 15 | 18 | ||
| Serum LDH level | ||||
| Normal | 53 | 72 | .001 | .0007 |
| >Normal | 26 | 34 | ||
| Ann Arbor stage | ||||
| I-II | 46 | 72 | .006 | .01 |
| III-IV | 36 | 44 | ||
| No. of extranodal sites | ||||
| 0-1 | 74 | 63 | .008 | .008 |
| >1 | 8 | 25 | ||
| Serum VEGF at diagnosis | ||||
| ≤228 pg/mL (median) | 41 | 71 | .01 | .04 |
| >228 pg/mL | 41 | 49 | ||
| ≤122 pg/mL (tertiles) | 27 | 70 | .07 | .15 |
| 123-314 pg/mL | 27 | 63 | ||
| >314 pg/mL | 28 | 46 | ||
| ≤95 pg/mL (quartiles) | 20 | 75 | .03 | .04 |
| 96-228 pg/mL | 21 | 67 | ||
| 229-410 pg/mL | 20 | 60 | ||
| >410 pg/mL | 21 | 38 | ||
| Presence of B-symptoms | ||||
| No | 67 | 64 | .01 | .08 |
| Yes | 15 | 40 | ||
| Histological grade | ||||
| Low | 18 | 78 | .02 | .03 |
| Intermediate | 40 | 65 | ||
| High | 22 | 36 | ||
| Age at diagnosis | ||||
| ≤60 | 42 | 69 | .02 | .03 |
| >60 | 40 | 50 | ||
| Gender | ||||
| Male | 38 | 61 | .74 | .86 |
| Female | 44 | 59 | ||
| Factor . | N . | 5-Year Survival (%) . | P . | |
|---|---|---|---|---|
| . | . | . | Wilcoxon Test . | Log-Rank Test . |
| International Prognostic Index | ||||
| 0-2 | 57 | 74 | <.0001 | <.0001 |
| 3-4 | 21 | 23 | ||
| WHO performance status | ||||
| 0-1 | 67 | 69 | <.0001 | <.0001 |
| 2-4 | 15 | 18 | ||
| Serum LDH level | ||||
| Normal | 53 | 72 | .001 | .0007 |
| >Normal | 26 | 34 | ||
| Ann Arbor stage | ||||
| I-II | 46 | 72 | .006 | .01 |
| III-IV | 36 | 44 | ||
| No. of extranodal sites | ||||
| 0-1 | 74 | 63 | .008 | .008 |
| >1 | 8 | 25 | ||
| Serum VEGF at diagnosis | ||||
| ≤228 pg/mL (median) | 41 | 71 | .01 | .04 |
| >228 pg/mL | 41 | 49 | ||
| ≤122 pg/mL (tertiles) | 27 | 70 | .07 | .15 |
| 123-314 pg/mL | 27 | 63 | ||
| >314 pg/mL | 28 | 46 | ||
| ≤95 pg/mL (quartiles) | 20 | 75 | .03 | .04 |
| 96-228 pg/mL | 21 | 67 | ||
| 229-410 pg/mL | 20 | 60 | ||
| >410 pg/mL | 21 | 38 | ||
| Presence of B-symptoms | ||||
| No | 67 | 64 | .01 | .08 |
| Yes | 15 | 40 | ||
| Histological grade | ||||
| Low | 18 | 78 | .02 | .03 |
| Intermediate | 40 | 65 | ||
| High | 22 | 36 | ||
| Age at diagnosis | ||||
| ≤60 | 42 | 69 | .02 | .03 |
| >60 | 40 | 50 | ||
| Gender | ||||
| Male | 38 | 61 | .74 | .86 |
| Female | 44 | 59 | ||
Abbreviations: WHO, World Health Organization; LDH, lactate dehydrogenase; VEGF, vascular endothelial growth factor.